Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry
Authors
Keywords
-
Journal
RHEUMATOLOGY INTERNATIONAL
Volume 41, Issue 4, Pages 751-762
Publisher
Springer Science and Business Media LLC
Online
2021-02-19
DOI
10.1007/s00296-020-04774-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7‐Year Interim Results
- (2019) Hermine I. Brunner et al. ARTHRITIS CARE & RESEARCH
- Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry
- (2019) Ariane Klein et al. RHEUMATOLOGY
- Biologics for the treatment of Juvenile Idiopathic Arthritis
- (2018) Dimitri Poddighe et al. CURRENT MEDICINAL CHEMISTRY
- The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
- (2018) Dimitrina Mihaylova et al. RHEUMATOLOGY INTERNATIONAL
- Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology
- (2018) Francesca Bovis et al. RHEUMATOLOGY INTERNATIONAL
- Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease
- (2018) Gerd Horneff et al. JOURNAL OF PEDIATRICS
- Risk of Serious Infections Associated with Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analyses
- (2018) Florence A. Aeschlimann et al. JOURNAL OF PEDIATRICS
- Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry
- (2018) A Klein et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Biologics in juvenile idiopathic arthritis: a narrative review
- (2017) Federica Vanoni et al. EUROPEAN JOURNAL OF PEDIATRICS
- Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry
- (2017) Ingrid Becker et al. ARTHRITIS CARE & RESEARCH
- Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance
- (2015) K L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan
- (2015) Shumpei Yokota et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of biologic therapies for the treatment of juvenile idiopathic arthritis
- (2015) Gerd Horneff Expert Opinion On Drug Safety
- Incidence of herpes zoster infections in juvenile idiopathic arthritis patients
- (2015) S. Nimmrich et al. RHEUMATOLOGY INTERNATIONAL
- A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis
- (2015) Rubén Burgos-Vargas et al. ARTHRITIS CARE & RESEARCH
- Biologic-Associated Infections in Pediatric Rheumatology
- (2015) Gerd Horneff Current Rheumatology Reports
- Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
- (2014) Hermine I Brunner et al. ANNALS OF THE RHEUMATIC DISEASES
- Infectious Complications in Juvenile Idiopathic Arthritis
- (2013) Andrew Hurd et al. Current Rheumatology Reports
- Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register
- (2012) Marieke H Otten et al. ANNALS OF THE RHEUMATIC DISEASES
- Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment
- (2012) Timothy Beukelman et al. ARTHRITIS AND RHEUMATISM
- Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis
- (2012) D. Hervás et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
- (2012) Nicolino Ruperto et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
- (2012) Fabrizio De Benedetti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems
- (2011) Lisa J. Herrinton et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Integrated safety in tocilizumab clinical trials
- (2011) Michael H Schiff et al. ARTHRITIS RESEARCH & THERAPY
- The safety profile of biologic therapies for juvenile idiopathic arthritis
- (2010) Philip J. Hashkes et al. Nature Reviews Rheumatology
- Development and validation of a composite disease activity score for juvenile idiopathic arthritis
- (2009) Alessandro Consolaro et al. ARTHRITIS AND RHEUMATISM
- Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
- (2009) Anja Strangfeld JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis
- (2008) Diane Lacaille et al. ARTHRITIS AND RHEUMATISM
- Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study
- (2008) Norman Ilowite et al. CLINICAL RHEUMATOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started